צמיחה צפויה ברווח למניה לשנה הבאה AC Immune (ACIU)

AC Immune relies on professional Swiss management and transparent R&D plans. However, the lack of sales and dependence on test outcomes create financial threats. The implementation of robotic biomaterial screening accelerates drug discovery. The forward earnings per share trend on this chart on GURU.Markets shows that 170.10 is the current level of the indicator, reflecting analyst consensus forecasts.

The scientific authority of AC Immune (ACIU) in Alzheimer's therapy translates into high precision in expert valuations of future cash flows. This coefficient measures analysts' average expectations for changes in earnings per share, reflecting the fundamental resilience of the business model. The metric allows for an assessment of the speed at which the company's profitability is revised based on the success of clinical trials. The trend in the projected growth rate of net income per share serves as a signal for timely risk hedging.